Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | KLK7 | P49862 | 2/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189234 | 0.91 | THRB (0.44) | ITGB3ITGA2BACEPTPN1PPARG | |
| SCHEMBL8188287 | 0.86 | THRB (0.36) | PPARGMEN1KMT2ALMNATTR | |
| SCHEMBL12584446 | 0.84 | VDR (0.31) | — | |
| SCHEMBL1526096 | 0.83 | THRB (0.39) | ITGB3ITGA2BACEPPARGKLK7 | |
| SCHEMBL6845190 | 0.82 | ITGB3 (0.44) | ITGB3ITGA2BACESCN9APTPN1 | |
| SCHEMBL12584373 | 0.82 | ITGB3 (0.44) | ITGB3ITGA2BACESCN9APTPN1 | |
| SCHEMBL13949739 | 0.81 | ACE (0.48) | ITGB3ITGA2BACESCN9APTPN1 | |
| SCHEMBL1526097 | 0.79 | THRB (0.34) | ITGB3PPARGPPARAKLK7KLK5 | |
| SCHEMBL1526077 | 0.79 | THRB (0.36) | ITGB3ITGA2BPPARGKLK7KLK5 | |
| SCHEMBL1526079 | 0.78 | MEN1 (0.33) | ITGB3PTPN1PPARGITGAVMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9579300-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9289395-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140314665-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | NANOPHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8668926-B1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC | 2014-03-11 | — | — | US | disclosed |
| WO-2008140507-A9 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM INC (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090022806-A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | ORDWAY RESEARCH INSTITUTE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090022806-A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | ORDWAY RESEARCH INSTITUTE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008140507-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314665-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | TSHR, TRHR, THRA | ITGB3 613/4885ITGA2B 1340/4885ACE 3272/4885 |
| US-20090022806-A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | TSHR, THRA, TRHR | ITGB3 665/4885ITGA2B 1433/4885ACE 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.